42
Views
0
CrossRef citations to date
0
Altmetric
Review

Tale of a Tegument Transactivator: The Past, Present and Future of Human CMV pp71

&
Pages 855-869 | Published online: 21 Sep 2012
 

Abstract

Herpesviruses assemble large virions capable of delivering to a newly infected cell not only the viral genome, but also viral proteins packaged within the tegument layer between the DNA-containing capsid and the lipid envelope. In this review, we describe the tegument transactivator of the β-herpesvirus human CMV, the pp71 protein. We present the known mechanistic features through which it activates viral gene expression during a lytic infection but fails to do so when the virus establishes latency, and describe how pp71 stimulates the cell cycle and may help infected cells avoid detection by the adaptive immune system. A historical overview of pp71 is extended with current perceptions of its roles during human CMV infections and suggestions for future avenues of experimentation.

Acknowledgements

The authors would like to thank H VanDeusen for the illustrations, and members of the laboratory for helpful comments.

Financial & competing interests disclosure

This work was supported by a grant from the NIH (AI074984) to RF Kalejta, who is a Vilas Associate and a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by a grant from the NIH (AI074984) to RF Kalejta, who is a Vilas Associate and a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.